Trials / Completed
CompletedNCT02848326
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 834 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and will characterize the dose/response relationship.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atogepant | Atogepant capsule. |
| DRUG | Placebo-matching Atogepant | Placebo-matching atogepant capsule. |
Timeline
- Start date
- 2016-09-06
- Primary completion
- 2018-04-02
- Completion
- 2018-04-23
- First posted
- 2016-07-28
- Last updated
- 2018-12-06
- Results posted
- 2018-12-06
Locations
75 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02848326. Inclusion in this directory is not an endorsement.